Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-05T01:41:06.874Z Has data issue: false hasContentIssue false
  • English
  • Français

The Nithsdale Schizophrenia Surveys. IX: Akathisia, Parkinsonism, Tardive Dyskinesia and Plasma Neuroleptic Levels

Published online by Cambridge University Press:  02 January 2018

Robin G. McCreadie ,
Lesley J. Robertson  and
David H. Wiles
Robin G. McCreadie*
Affiliation:
Crichton Royal Hospital, Dumfries DG1 4TG, Scotland
Lesley J. Robertson
Affiliation:
Crichton Royal Hospital, Dumfries, Greater Glasgow Health Board
David H. Wiles
Affiliation:
Crichton Royal Hospital, Dumfries
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

Of all known schizophrenics living in Nithsdale, south-west Scotland, 146 (88%) were examined for the presence of the three principal movement disorders secondary to antipsychotic medication, namely akathisia, tardive dyskinesia and Parkinsonism. Of these, 18% had akathisia, 5% pseudoakathisia, 29% tardive dyskinesia, 8% persistent tardive dyskinesia, and 27% Parkinsonism. No movement disorder was seen in 44%, 36% had one and 20% had more than one movement disorder. Plasma neuroleptic levels at the time of clinical assessment were measured by the radioreceptor technique. Correlations between dose and plasma level were low; the ratio of mean plasma concentration to mean dose was greatest with fluphenazine decanoate and lowest for sulpiride. The concentration:dose ratio was higher in the elderly. There was no relationship between neuroleptic levels and akathisia, Parkinsonism or tardive dyskinesia. Additional psychotropic medication influenced neuroleptic levels. In 9% of patients receiving oral antipsychotic medication, no drug was detected in plasma.

Type
Papers
Information
The British Journal of Psychiatry , Volume 160 , Issue 6 , June 1992 , pp. 793 - 799
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1967) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.Google Scholar
Ayd, F. J. (1961) A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association, 175, 1054–1060.Google Scholar
Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.Google Scholar
Barnes, T. R. E. & Braude, W. M. (1985) Akathisia variants and tardive dyskinesia. Archives of General Psychiatry, 42, 874–878.Google Scholar
Bergen, J. A., Eyland, E. A., Campbell, J. A., et al (1989) The course of tardive dyskinesia in patients on longterm neuroleptics. British Journal of Psychiatry, 154, 523–528.Google Scholar
Braude, W. M., Barnes, T. R. E. & Gore, S. M. (1983) Clinical characteristics of akathisia. A systematic investigation of acute psychiatric in-patient admissions. British Journal of Psychiatry, 143, 139–150.Google Scholar
Creese, I., Lader, S. & Rosenberg, B. (1981) Radioreceptor assay for neuroleptic drugs. In Clinical Pharmacology in Psychiatry: Neuroleptic and Antidepressant Research (eds Usdin, E., Dane, S. G., Gram, L., et al). London: Macmillan.Google Scholar
Davis, J. M. (1985) Antipsychotic drugs. In Comprehensive Textbook of Psychiatry (eds Kaplan, H. I. & Sadock, B. J.). Baltimore: Williams & Wilkins.Google Scholar
El-Yousef, K. M. & Manier, D. H. (1974) The effect of benztropine mesylate on plasma levels of butaperazine maleate. American Journal of Psychiatry, 131, 471–472.Google Scholar
Friis, T., Christensen, T. R. & Gerlach, J. (1983) Sodium valproate and biperiden in neuroleptic induced akathisia, parkinsonism and hyperkinesia. Acta Psychiatrica Scandinavica, 67, 178–187.Google Scholar
Gardos, G., Cole, J. O., Haskell, D., et al (1988) The natural history of tardive dyskinesia. Journal of Clinical Psychopharmacology, 8 (suppl. 4), 31s–37s.Google Scholar
Gibb, W. R. G. & Lees, A. J. (1986) The clinical phenomenon of akathisia. Journal of Neurology, Neurosurgery and Psychiatry, 49, 861–866.Google Scholar
Gram, L. F., Fredricson-Overo, K. & Kirk, L. (1973) Tricyclic antidepressants and benzodiazepines; a drug combination without pharmacokinetic interaction in man. Nordisk Psychiatrisk Tiddskrift, 27, 434–438.CrossRefGoogle Scholar
Hansen, L. B., Larsen, N. E. & Gulmann, N. (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology, 78, 112–115.Google Scholar
Jeste, D. V., Rosenblatt, J. E., Wagner, R. L., et al (1979) High serum neuroleptic levels in tardive dyskinesia? New England Journal of Medicine, 301, 1184.Google Scholar
Jeste, D. V., DeLisi, L. E., Zalcman, S., et al (1981) A biochemical study of tardive dyskinesia in young male patients. Psychiatry Research, 4, 327–331.Google Scholar
Jeste, D. V., Linnoila, M., Wagner, R. L., et al (1982) Serum neuroleptic concentrations and tardive dyskinesia. Psychopharmacology, 76, 377–380.Google Scholar
Kane, J. M., Woerner, M. & Lieberman, J. (1988) Tardive dyskinesia: prevalence, incidence and risk factors. Journal of Clinical Psychopharmacology, 8 (suppl. 4), 52s–56s.CrossRefGoogle ScholarPubMed
Kennedy, P. F., Hershon, H. I. & Mcguire, R. J. (1971) Extrapyramidal disorders after prolonged phenothiazine therapy. British Journal of Psychiatry, 118, 509–518.Google Scholar
Kolakowska, T., Wiles, D. H., Gelder, M. G., et al (1976) Clinical significance of plasma chlorpromazine levels. Psychopharmacology, 49, 101–107.Google Scholar
Krska, J., Sampath, G., Shah, A., et al (1986) Radioreceptor assay of serum neuroleptic levels in psychiatric patients. British Journal of Psychiatry, 148, 187–193.CrossRefGoogle ScholarPubMed
Logan, S., Curry, S. & Lader, M. (1975) Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. British Journal of Clinical Pharmacology, 2, 197–208.Google Scholar
McCreadie, R. G. (1982) The Nithsdale Schizophrenia Survey: I Psychiatric and social handicaps. British Journal of Psychiatry, 140, 582–586.CrossRefGoogle ScholarPubMed
McCreadie, R. G., Barron, E. T. & Winslow, G. S. (1982) The Nithsdale Schizophrenia Survey: II Abnormal movements. British Journal of Psychiatry, 140, 587–590.Google Scholar
Mindham, R. H. S., Gaind, R., Anstee, B. H., et al (1972) Comparison of amantadine, orphenadrine and placebo in the control of phenothiazine-induced parkinsonism. Psychological Medicine, 2, 406–413.Google Scholar
Perel, J. M., O'Brien, L., Black, N. B., et al (1974) Imipramine and chlorpromazine in hepatic microsomal systems. In The Phenothiazines and Structurally Related Drugs (eds Forrest, I. S., Carr, W. & Usdin, E.). New York: Raven Press.Google Scholar
Rivera-Calimlin, L., Castenada, L. & Lasagna, L. (1973) Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology and Therapeutics, 14, 978–986.Google Scholar
Robinson, A. D. T. & McCreadie, R. G. (1986) The Nithsdale Schizophrenia Survey: V Follow-up of tardive dyskinesia at 3½ years. British Journal of Psychiatry, 149, 621–623.CrossRefGoogle Scholar
Schooler, N. R. & Kane, J. M. (1982) Research diagnoses for tardive dyskinesia. Archives of General Psychiatry, 39, 486–487.Google Scholar
Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, suppl. 212, 11–19.CrossRefGoogle Scholar
Simpson, G. M., Cooper, T. B., Bark, N., et al (1980) Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Archives of General Psychiatry, 37, 205–208.Google Scholar
Steck, H. (1954) Le syndrome exrapyramidal et diencephalique au cours des traitements au largactil et au serpasil. Annates Medico-Psychologiques (Paris), 112, 734–744.Google Scholar
US Department of Health, Education and Welfare (1976) Abnormal involuntary movements scale (AIMS). In ECDEU Assessment Manual (ed. Guy, W.), pp. 534–537. Rockville, Maryland: US Department of Health, Education and Welfare.Google Scholar
Van Putten, T. (1974) Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry, 31, 67–72.CrossRefGoogle ScholarPubMed
Van Putten, T. (1975) The many faces of akathisia. Comprehensive Psychiatry, 16, 43–47.Google Scholar
Van Putten, T., May, P. R. A. & Marder, S. R. (1984) Akathisia with haloperidol and thiothixene. Archives of General Psychiatry, 41, 1036–1039.CrossRefGoogle ScholarPubMed
Widerlov, E., Haggstrom, J. E., Kilts, C. D., et al (1982) Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia. Acta Psychiatrica Scandinavica, 66, 294–305.Google Scholar
Yassa, R. & Nair, V. (1989) Mild tardive dyskinesia: an 8–year follow-up study. Acta Psychiatrica Scandinavica, 81, 139–140.CrossRefGoogle Scholar
Yesavage, J. A., Tanke, E. D. & Sheikh, J. I. (1987) Tardive dyskinesia and steady-state serum levels of thiothixene. Archives of General Psychiatry, 44, 913–915.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.